Saturday 17 October 2026
Export PHIO’s income statement to Excel — free account
Phio Pharmaceuticals Corp.
PHIO Healthcare Biotechnology
In the quarter to June 2026, EPS grew 20.0% and free cash flow fell 58.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.87
0.06
−6.45%
Follow PHIO
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | 1 | 4 | 3 | 5 |
P/E ratio |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | — | — | 32.12 | 17.05 | 195.04 | 63.83 |
Altman Z-Score |
— | — | — | — | — | — | (18.25) | (7.57) | (34.20) | (7.18) |
P/FCF ratio |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | — | (38.91) | (7.59) | (82.19) | (10.95) |
P/Operating CF |
— | — | — | — | — | — | (1.72) | (1.35) | (5.94) | (3.12) |
P/B ratio |
— | — | — | — | — | — | 0.76 | 0.17 | 7.13 | 0.58 |
Price to Tangible BV |
— | — | — | — | — | — | 0.76 | 0.17 | 7.13 | 0.58 |
EV/Sales |
— | — | — | — | — | — | (16.22) | (91.14) | 140.85 | (129.54) |
EV/EBITDA |
— | — | — | — | — | — | 0.25 | 1.73 | 0.00 | 0.97 |
EV/Operating CF |
— | — | — | — | — | — | 0.26 | 1.67 | (0.99) | 1.12 |
EV/FCF |
— | — | — | — | — | — | 0.25 | 1.63 | (0.97) | 1.12 |
Quick Ratio |
15.69 | 5.30 | 5.20 | 6.10 | 7.86 | 6.51 | 3.71 | 8.56 | 1.60 | 5.10 |
Current Ratio |
16.03 | 5.65 | 5.71 | 6.42 | 8.06 | 6.91 | 3.88 | 8.69 | 1.69 | 5.16 |
Net Debt/EBITDA |
2.28 | 0.73 | 0.79 | 1.04 | 1.79 | 1.61 | 0.74 | 2.05 | 0.26 | 1.45 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1.47% | 5.11% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.07 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
Operating CF/Net income |
0.92 | 0.99 | 0.99 | 1.06 | 0.89 | 1.00 | 0.97 | 1.02 | 0.76 | 0.70 |
Capex/Depreciation |
(4.00) | 4.00 | (0.09) | (1.70) | (0.68) | (0.26) | (1.07) | (0.06) | (2.90) | (0.08) |
| (69.95%) | (114.83%) | (116.61%) | (70.06%) | (76.04%) | (93.73%) | (92.19%) | (95.52%) | (271.79%) | (136.49%) | |
| (63.90%) | (94.69%) | (97.63%) | (60.45%) | (64.96%) | (73.97%) | (76.26%) | (75.80%) | (142.35%) | (90.15%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(43.17%) | (151.39%) | (140.71%) | (107.39%) | (60.97%) | (67.00%) | (158.22%) | (54.21%) | (686.06%) | (103.66%) |
Average Days of Receivables |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 20,476.19% | 3,134.78% | 67,106.67% | 28,500.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 22,419.05% | 2,301.45% | 26,740.00% | 19,047.37% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1,428.57% | 204.35% | 2,093.33% | 3,978.95% |
Graham Net Nets |
— | — | — | — | — | — | 1.15 | 5.70 | 0.12 | 2.47 |
Graham Number |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | — | — | (201.86%) | (545.18%) | (104.31%) | (224.89%) |
Free Cash Flow Yield |
— | — | — | — | — | — | (199.58%) | (328.45%) | (74.36%) | (181.96%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.88 | 115.00 | 37.50 | 190.00 |
Operating CF per Share |
(1.33) | (9.04) | (46.33) | (96.03) | (99.81) | (207.11) | (2,010.47) | (6,266.67) | (23,785.00) | (77,600.00) |
Capex per Share |
0.00 | 0.01 | (0.02) | (0.96) | (0.43) | (0.45) | (16.74) | (4.17) | (507.50) | (40.00) |
Free Cash Flow per Share |
(1.34) | (9.03) | (46.35) | (96.99) | (100.24) | (207.55) | (2,027.21) | (6,270.83) | (24,292.50) | (77,640.00) |
Cash per Share |
3.51 | 6.84 | 36.59 | 93.67 | 202.92 | 336.33 | 1,624.19 | 12,440.83 | 9,077.50 | 129,560.00 |
Shareholders Equity per Share |
3.37 | 6.00 | 33.32 | 85.81 | 184.61 | 306.28 | 1,336.74 | 11,315.00 | 4,582.50 | 108,550.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.37 | 6.00 | 33.32 | 85.81 | 184.61 | 306.28 | 1,336.74 | 11,315.00 | 4,582.50 | 108,550.00 |
Free Cash Flow |
(7.99) | (7.10) | (10.75) | (12.25) | (11.91) | (8.82) | (8.72) | (7.52) | (9.72) | (7.76) |
Working Capital |
20.14 | 4.72 | 7.69 | 10.51 | 21.66 | 12.97 | 5.42 | 13.41 | 1.57 | 10.56 |
Capital Expenditures |
(0.01) | 0.01 | 0.00 | (0.12) | (0.05) | (0.02) | (0.07) | 0.00 | (0.20) | 0.00 |
Net Current Asset Value |
20.14 | 4.72 | 7.69 | 10.47 | 21.49 | 12.44 | 5.01 | 13.41 | 1.57 | 10.56 |
EV/EBIT |
— | — | — | — | — | — | 0.25 | 1.71 | 0.00 | 0.96 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.43 | 0.04 | 13.53 | 0.21 |
Price to Operating Income |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.27 | 1.00 | 9.33 | 0.39 | 0.56 | 0.46 | 0.32 | 0.47 | 0.28 | 0.46 |
Cash ROIC |
(19.41%) | (70.30%) | (66.30%) | (54.04%) | (25.87%) | (32.03%) | (66.32%) | (26.40%) | (177.84%) | (32.61%) |
Accounts Receivable Turnover |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | — | — | — | — |
Average Payables |
0.34 | 0.46 | 0.72 | 0.53 | 0.51 | 0.77 | 0.68 | 0.53 | 0.71 | 1.04 |
Average Assets |
13.61 | 7.55 | 11.09 | 18.99 | 20.45 | 11.89 | 11.68 | 9.71 | 8.75 | 12.28 |
Average Common Equity |
12.44 | 6.23 | 9.28 | 16.39 | 17.47 | 9.38 | 9.66 | 7.71 | 4.58 | 8.11 |
Columns are period end dates